^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    PKN1 (Protein Kinase N1)

    i
    Other names: PKN1, Protein Kinase N1, PRK1, PAK1, PKN, Protein Kinase C-Like 1, PRKCL1, DBK, Serine/Threonine-Protein Kinase N1, Protease-Activated Kinase 1, Protein Kinase C-Like PKN, Protein Kinase PKN-Alpha, MGC46204, PAK-1, Protein Kinase C-Related Kinase 1, Serine/Threonine Protein Kinase N, Protein-Kinase C-Related Kinase 1, Serine-Threonine Protein Kinase N, Serine-Threonine Kinase N, PKN-ALPHA
    Associations

    News

    Trials
    over2years
    The role of PKN1 in glioma pathogenesis and the antiglioma effect of raloxifene targeting PKN1. (PubMed, J Cell Mol Med)
    We showed that Ralo effectively targets PKN1, inhibits GBM cells proliferation and migration and sensitizes GBM cells to the major chemotherapeutic drug, Temozolomide. Ralo also reverses the effect of PKN1 on YAP activation. Thus, we confirm that PKN1 contributes to the pathogenesis of gliomas and may be a potential target for Ralo adjuvant glioma therapy.
    Journal
    |
    PKN1 (Protein Kinase N1)
    |
    temozolomide • raloxifene hydrochloride
    over2years
    Molecular typing and mutational characterization of rectal neuroendocrine neoplasms. (PubMed, Cancer Med)
    This study evaluated risk factors for regional lymphatic and/or distant metastases, identified high-frequency mutated genes, mutation signatures, altered signaling pathways through NGS. Rectal NENs were divided into two molecular types. This helps to evaluate the likelihood of metastasis, formulate follow-up strategies for patients and provide a target for future research on precision treatment of rectal NENs. PARP inhibitors, MEK inhibitors, mTOR/AKT/PI3K and Wnt signaling pathway inhibitors may be effective drugs for the treatment of metastatic rectal NENs.
    Journal • Tumor mutational burden • BRCA Biomarker • PARP Biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • NF1 (Neurofibromin 1) • BCL2L1 (BCL2-like 1) • KMT2C (Lysine Methyltransferase 2C) • MERTK (MER Proto-Oncogene, Tyrosine Kinase) • FAT3 (FAT Atypical Cadherin 3) • SOX9 (SRY-Box Transcription Factor 9) • DAXX (Death-domain associated protein) • PKN1 (Protein Kinase N1)
    |
    TP53 mutation • BRCA1 mutation • NF1 mutation • FAT3 mutation